

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) A method for promoting axonal growth comprising treating a neuron with an NF-AT agonist.
2. (Original) The method of claim 1, wherein said NF-AT agonist interacts with calcineurin and increases the dephosphorylation of NF-AT.
3. (Original) The method of claim 1, wherein said NF-AT agonist binds NF-AT and increases its nuclear localization.
4. (Amended) The method of claim 1, wherein the NF-AT agonist is calcineurin or an agent that activates or upregulates the expression of calcineurin.
5. (Original) The method of claim 1, wherein the NF-AT agonist is an inhibitor of GSK-3.
6. (Original) The method of claim 5, wherein the inhibitor of GSK-3 is selected from the group consisting of an RNAi molecule, a ribozyme or a DNA enzyme that inhibits the expression of GSK3.
7. (Amended) The [[A]] method for promoting axonal growth comprising treating a neuron with a composition comprising an NF-AT agonist and of claim 1 further comprising administering another agent selected from the group consisting of: a neurotrophic factor, a neuropoietic factor, inosine, a fibroblast growth factor, an insulin-like growth factor, a platelet-derive growth factor, an anti-inflammatory, anti-NGF, anti-BDNF, anti-IGF-I, transforming growth factor-beta 1, other agents that increase production of inducible-nitric oxide synthase (i-NOS), an activator of macrophages, LPS, indomethacin, and a leukemia inhibitory factor (LIF).
- 8.-19. (Cancelled)
20. (New) The method of claim 1, wherein said method comprises administering an NF-AT agonist in a biodegradable nerve conduit.